Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk

Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk

Background: The optimal adjuvant endocrine treatment in premenopausal patients with hormone receptor-positive, HER2-negative (HRpos/HER2neg) early breast cancer (eBC) remains debated, particularly the choice between aromatase inhibitors plus ovarian function suppression (AI + OFS) or tamoxifen (TAM)...

Full description

Saved in:
Bibliographic Details
Main Authors: Volkmar Müller, Manuel Hörner, Marc Thill, Maggie Banys-Paluchowski, Sabine Schmatloch, Peter A. Fasching, Nadia Harbeck, Dagmar Langanke, Sabrina Uhrig, Lothar Häberle, Dorothea Fischer, Alexander Hein, Tanja N. Fehm, Chloë Goossens, Jürgen Terhaag, Uwe Heilenkötter, Peter Dall, Christian Rudlowski, Rachel Wuerstlein, Mustafa Aydogdu, Mignon-Denise Keyver-Paik, Carolin Hammerle, Natalija Deuerling, Elmar Stickeler, Bahriye Aktas, Erik Belleville, Martin Thoma, Nina Ditsch, Yasmin Baila, Christian Roos, Christian Mann, Caterina Iuliano, Sara Y. Brucker, Andreas Schneeweiss, Andreas D. Hartkopf
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:Breast
Subjects:
Early breast cancer
Endocrine therapy
Tamoxifen
Aromatase inhibitor
Hormone receptor-positive
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977625004758
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S0960977625004758

Similar Items